WO2023025799A1 - Human milk oligosaccahrides in cosmetics - Google Patents
Human milk oligosaccahrides in cosmetics Download PDFInfo
- Publication number
- WO2023025799A1 WO2023025799A1 PCT/EP2022/073480 EP2022073480W WO2023025799A1 WO 2023025799 A1 WO2023025799 A1 WO 2023025799A1 EP 2022073480 W EP2022073480 W EP 2022073480W WO 2023025799 A1 WO2023025799 A1 WO 2023025799A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- derivative
- human milk
- range
- composition
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 46
- 235000020256 human milk Nutrition 0.000 title claims abstract description 22
- 210000004251 human milk Anatomy 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 105
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 36
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 33
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 33
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 33
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims abstract description 23
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 17
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 17
- 238000002845 discoloration Methods 0.000 claims abstract description 15
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 claims abstract description 14
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 claims abstract description 14
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 claims abstract description 14
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 42
- -1 6’sialyllactose sodium salt Chemical class 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 10
- 239000012071 phase Substances 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 9
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 9
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 9
- 239000008346 aqueous phase Substances 0.000 claims description 7
- LTWFUJWFLMHANB-TZCPRLTCSA-M sodium;(2s,4s,5r,6r)-5-acetamido-2-[(2r,3s,4s,5r,6s)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3r,4r,5r)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1r,2r)-1,2,3-trihydroxypropyl]oxane-2-carboxylate Chemical group [Na+].O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C([O-])=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O LTWFUJWFLMHANB-TZCPRLTCSA-M 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 claims 1
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 abstract description 4
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 abstract description 4
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 abstract description 4
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 abstract description 4
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 description 21
- 239000003995 emulsifying agent Substances 0.000 description 15
- 229910019142 PO4 Inorganic materials 0.000 description 11
- 239000010452 phosphate Substances 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000006210 lotion Substances 0.000 description 7
- 239000000654 additive Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- UPOYFZYFGWBUKL-UHFFFAOYSA-N amiphenazole Chemical compound S1C(N)=NC(N)=C1C1=CC=CC=C1 UPOYFZYFGWBUKL-UHFFFAOYSA-N 0.000 description 4
- 229950001798 amiphenazole Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000007764 o/w emulsion Substances 0.000 description 4
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- VMWYCXKMRSTDSP-GIGDJUIZSA-N (2r,4s,5r,6r)-5-acetamido-4-hydroxy-2-{[(2r,3r,4s,5r,6s)-3,4,5-trihydroxy-6-{[(2r,3r,4r,5r)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxy}oxan-2-yl]methoxy}-6-[(1r,2r)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O1 VMWYCXKMRSTDSP-GIGDJUIZSA-N 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940112262 ceteareth-2 phosphate Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 2
- GKKMCECQQIKAHA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCCCCCCOP(O)(O)=O GKKMCECQQIKAHA-UHFFFAOYSA-N 0.000 description 2
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- XTJKNGLLPGBHHO-HNNXBMFYSA-N (2s)-5-(diaminomethylideneamino)-2-(dodecanoylamino)pentanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCCN=C(N)N XTJKNGLLPGBHHO-HNNXBMFYSA-N 0.000 description 1
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- VOFRZBBLONRUHY-KVVVOXFISA-N 2-(2-hydroxyethylamino)ethanol;2-[2-[2-[(z)-octadec-9-enoxy]ethoxy]ethoxy]ethyl dihydrogen phosphate Chemical compound OCCNCCO.CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOP(O)(O)=O VOFRZBBLONRUHY-KVVVOXFISA-N 0.000 description 1
- GLGQRQQFWLTGES-UHFFFAOYSA-N 2-[2-[2-[2-[2-(2-decoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCOCCOCCOCCOCCOCCOCCO GLGQRQQFWLTGES-UHFFFAOYSA-N 0.000 description 1
- DKELNUBFYRNPMB-UHFFFAOYSA-N 2-decoxyethanol;phosphoric acid Chemical compound OP(O)(O)=O.CCCCCCCCCCOCCO DKELNUBFYRNPMB-UHFFFAOYSA-N 0.000 description 1
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 description 1
- XGLVOXPOOUTSDB-UHFFFAOYSA-N 3-(chloromethyl)-1,2-thiazol-4-one Chemical compound ClCC1=NSCC1=O XGLVOXPOOUTSDB-UHFFFAOYSA-N 0.000 description 1
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
- DLICJXPMMTZITN-UHFFFAOYSA-N 3-methyl-1,2-thiazol-4-one Chemical compound CC1=NSCC1=O DLICJXPMMTZITN-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- 239000002610 basifying agent Substances 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- IEQCXFNWPAHHQR-YKLSGRGUSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IEQCXFNWPAHHQR-YKLSGRGUSA-N 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 229940096584 c12-15 pareth-3 Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940031766 diethanolamine cetyl phosphate Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- OSORMYZMWHVFOZ-UHFFFAOYSA-N phenethyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCCC1=CC=CC=C1 OSORMYZMWHVFOZ-UHFFFAOYSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229940045898 sodium stearoyl glutamate Drugs 0.000 description 1
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000011493 spray foam Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940072029 trilaureth-4 phosphate Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Definitions
- the present invention relates to cosmetic compositions comprising Vitamin B6 or a derivative thereof and at least one human milk oligosaccharide (HMOs) selected from the group consisting of 3’sialyllactose, 6’sialyllactose and lacto-N-tetraose as well as to a use of said HMOs for suppressing discoloration of Vitamin B6 or a derivative thereof.
- HMOs human milk oligosaccharide
- Vitamin B6 or derivatives thereof such as pyridoxine hydrochloride are used in cosmetic applications to exert beneficial physiological effects, such as to stimulate the healthy-looking appearance of hair and contribute to the efficacy of anti-dandruff products.
- Vitamin B6 appears to reduce sebum levels and limit the area of oily spots.
- Vitamin B6 tends to discolor upon storage which is highly unwanted as it leads to an unpleasant optical appearance of the respective product.
- HMOs Human milk oligosaccharides
- compositions containing Vitamin B6 respectively derivatives thereof such as in particular pyridoxine hydrochloride can be effectively reduced by the addition of certain human milk oligosaccharides.
- the present invention relates to cosmetic compositions comprising a human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N-tetraose and Vitamin B6 or a derivative thereof.
- the present invention relates to the use of a human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N- tetraose for suppressing discoloration of Vitamin B6 or a derivative thereof, preferably in aqueous compositions and optionally appreciating the effect.
- a human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N- tetraose for suppressing discoloration of Vitamin B6 or a derivative thereof, preferably in aqueous compositions and optionally appreciating the effect.
- the present invention relates to a method for reducing discoloration of compositions containing Vitamin B6 and/or a derivative thereof, said method comprising preparing a composition comprising Vitamin B6 and/or a derivative thereof, one or more human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N-tetraose and a cosmetically acceptable carrier, which carrier preferably comprises water, and optionally storing the respective composition for at least 1 , more preferably for at least 2, most preferably for at least 4 weeks, such as e.g. for 6 weeks.
- the invention relates to the use of a combination of Vitamin B6 and/or a derivative thereof and one or more human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N-tetraose, for the preparation of storage stable topical composition.
- These compositions exhibit an excellent storage stability in view of preventing/suppressing discoloration compared to a control not comprising the respective HMO(s).
- Said compositions can be prepared by admixing Vitamin B6 and/or a derivative thereof and at least one human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N-tetraose into a cosmetically acceptable carrier, which carrier preferably comprises water.
- compositions according to the present invention may comprise only one HMO as defined herein as well as only one Vitamin B6/ Vitamin B6 derivative, which embodiment is preferred, but also may comprise mixtures of HMOs as well mixtures of Vitamin B6 and its derivatives as defined herein.
- suppress/ suppressing discoloration refers to a reduced discoloration of the composition according to the present invention compared to control.
- the suppression of discoloration according to the present invention is reflected by reduced b-values (according to the CIELAB colorspace) compared to the respective control not comprising the HMO upon storage, such as storage for at least 2 weeks at RT (about 22°C) at daylight in clear glass vials/containers as outlined in the example.
- Vitamin B6 and derivatives thereof refers in particular to pyridoxine hydrochloride [58-56-0], pyridoxal [CAS-Nr. 66-72-8] and pyridoxamin [CAS-Nr. 85-87- 0], In all embodiments, particularly preferred is the use of pyridoxine hydrochloride also known as Vitamin B6 hydrochloride or Vitamin B6 which is e.g. available as Pyridoxine hydrochloride or Pyridoxine Hydrochloride 98 DC at DSM Nutritional Products AG, (4303 Kaiseraugst, Switzerland).
- the amount of Vitamin B6 or a derivative thereof such as in particular pyridoxine hydrochloride in the compositions according to the present invention is selected in the range of 0.02 to 6 wt. %, preferably in the range of 0.05 to 4wt. %, most preferably in the range of 0.1 to 3 wt. %, based on the total weight of the composition.
- HMOs are composed of the five monosaccharides glucose (Glc), galactose (Gal), N- acetylglucosamine (GIcNAc), fucose (Fuc) and sialic acid (Sia), with N-acetylneuraminic acid (Neu5Ac) as the predominant if not only form of Sia. More than two hundred different HMOs have been identified so far.
- sialyllactoses as used herein refers to sialylated HMO’s as well as salts thereof (preferably the sodium salts) such as in particular 3’sialyllactose, 6’sialyllactose as well as the respective sodium salts thereof (CAS No’s: 35890-39-2 (3’sialyllactose); 128596-80-5 (3’sialyllactose sodium salt); 35890-39-2 (6’sialyllactose); 157574-76-0 (6’sialyllactose sodium salt)). Most preferred in all embodiments of the present invention is the use of 3’sialyllactose sodium salt and/ or 6’sialyllactose sodium salt.
- Lacto-N-tetraose is a highly abundant neutral core HMO in human milk (CAS No: 141 16-68-8).
- HMOs can be isolated from breast milk or they can be produced chemically or biochemically.
- the source of the HMO is not essential. It is clear that HMOs from different sources can be used. In the embodiment of the present invention the one or more HMO may not only serve as an agent to reduce discoloration but may also excerpt positive effect on the skin.
- the HMO is selected from the group consisting of 3’sialyllactose sodium salt and 6'sialyllactose sodium salt as well as mixtures thereof, as these HMOs are particularly effective.
- the total amount of HMO(s) according to the present invention in the compositions according to the present invention is preferably selected in the range from 0.01 to 10 wt.-%, more preferably from 0.1 to 7.5 wt.-%, most preferably from 0.2 to 5 wt.-%, based on the total weight of the composition. Further suitable ranges are from 0.25 to 2.5 wt.-%, from 0.5 to 2 wt.-%, from 0.1 to 1 wt.-%, from 0.25 to 0.75 wt.-% and from 0.3 to 0.6 wt.-%. Particularly preferred ranges according to the present invention are from 0.1 to 5 wt.-%, more preferably from 0.25 to 5 wt.-%, such as from 0.3 to 5 wt.-%.
- the use level (in weight-%) of the HMO(s) is higher than the one of Vitamin B6 and/or a derivative thereof, i.e. the HMO(s) is/ are used in an excess.
- the weightratio (w/w) between the HMO(s) and Vitamin B6 or a derivative thereof is selected in the range from 50:1 to 1 :1 , more preferably in the range from 25:1 to 1 :1 , most preferably in the range from 15:1 to 1 :1 such as from 15:1 to 5: 1. Further preferred ranges are 10:1 to 7.5:1 , 10:1 to 5:1 or 10:1 to 2:1 and 10:1 to 1 :1.
- cosmetic composition refers to cosmetic compositions which are used to treat, care for or improve the appearance of the skin and/or the scalp.
- compositions preferably are aqueous compositions, i.e. compositions which comprise water.
- the water content in the compositions according to the present invention is selected in the range from 30 to 90 wt.-%, from 40 to 90 wt.-%, from 45 to 90 wt.-% or from 50 to 90 wt.-%, based on the total weight of the composition. Further suitable ranges are from 30 to 75 wt.-%, from 30 to 70 wt.-%, from 30 to 60 wt.-% and from 40 to 60 wt.-%.
- compositions according to the present invention are cosmetic compositions intended to be topically applied to mammalian keratinous tissue such as in particular to human skin or the human scalp.
- Such compositions are also called dermatological compositions.
- the cosmetic compositions are topical cosmetic (i.e. dermatological) compositions with all the definitions and preferences as given herein.
- the topical compositions according to the present invention may be leave-on or rinse- off compositions, and include any product applied to a human body, primarily for improving appearance, cleansing, odor control or general aesthetics.
- the cosmetic compositions of the present invention are leave-on compositions.
- compositions according to the invention intended for topical application comprise a physiologically acceptable medium, i.e. a medium compatible with keratinous substances, such as the skin, mucous membranes, and keratinous fibers.
- physiologically acceptable medium is a cosmetically acceptable carrier.
- the carrier comprises water.
- cosmetic carrier also referred to herein as carrier refers to all vehicles/ carriers conventionally used in cosmetic compositions, i.e. which are suitable for topical application to the keratinous tissue, have good aesthetic properties, are compatible with the actives present in the composition, and will not cause any unreasonable safety or toxicity concerns.
- Such carriers are well-known to one of ordinary skill in the art, and can include one or more compatible liquid(s) or solid filler diluent(s), excipient(s), additive(s) or vehicle(s) which are suitable for application to skin.
- compositions of the present invention preferably comprise from about 50% to about 99.999%, more preferably from about 60% to about 99.99%, still more preferably from 75% to about 99%, and most preferably, from about 80% to about 98% such as about 90% to about 98%, by weight of the composition, of a carrier, based on the total weight of the composition.
- the carrier consists furthermore of at least 30 wt. %, more preferably of at least 40 wt.-%, most preferably of at least 45 wt.-% of water, such as in particular of 50 to 90 wt.-% of water.
- the cosmetic compositions in accordance with the invention can be in the form of a liquid, lotion, a thickened lotion, a gel, a cream, a milk, an ointment, a paste, a powder, a make-up, or a solid tube stick and can be optionally be packaged as an aerosol and can be provided in the form of a mousse such as an aerosol mousse, a foam or a spray foam, a spray, a stick.
- Vitamin B6 and/or a derivative thereof and the respective HMO(s) are formulated into lotions, creams, gels, and tonics.
- These product forms may be used for a number of applications, including, but not limited to, hand and body lotions, facial moisturizers, anti-ageing preparations, make-ups including foundations, and the like. Any additional components required to formulate such products vary with product type and can be routinely chosen by one skilled in the art.
- compositions of the present invention are formulated as an aerosol and applied to the skin as a spray-on product, a propellant is added to the composition.
- compositions according to the present invention can be prepared by conventional methods in the art such as e.g. by admixing the Vitamin B6 and/or a derivative thereof and the respective HMO(s) with all the definitions and preferences given herein with the cosmetically acceptable carrier.
- the cosmetic composition may comprise further ingredients, which may form part of the carrier.
- ingredients are particularly surfactants, emulsifiers, thickeners, and oils.
- surfactants, emulsifiers, thickeners, and oils are well known to a person skilled in the art.
- the cosmetic compositions of the invention may comprise further conventional (cosmetic) adjuvants and additives, such as preservatives/antioxidants, fatty substances/oils, water, organic solvents, silicones, thickeners, softeners, emulsifiers, antifoaming agents, aesthetic components such as fragrances, surfactants, fillers, anionic, cationic, non-ionic or amphoteric polymers or mixtures thereof, propellants, acidifying or basifying agents, dyes, colorings/colorants, abrasives, absorbents, chelating agents and/ or sequestering agents, essential oils, skin sensates, astringents, pigments or any other ingredients usually formulated into such compositions.
- cosmetic adjuvants and additives such as preservatives/antioxidants, fatty substances/oils, water, organic solvents, silicones, thickeners, softeners, emulsifiers, antifoaming agents, aesthetic components such as fragrances, surfactants, fillers, anionic
- compositions according to the present invention are suitable for the compositions according to the present invention.
- the necessary amounts of the cosmetic and dermatological adjuvants and additives can, based on the desired product, easily be determined by the skilled person.
- the additional ingredients can either be added to the oily phase, the aqueous phase or separately as deemed appropriate.
- the mode of addition can easily be adapted by a person skilled in the art.
- cosmetic excipients examples include cosmetic excipients, diluents, adjuvants, additives as well as active ingredients commonly used in the skin care industry which are suitable for use in the cosmetic compositions of the present invention are for example described in the International Cosmetic Ingredient Dictionary & Handbook by Personal Care Product Council (http://www.personalcarecouncil.org/), accessible by the online INFO BASE (http://online.personalcarecouncil.org/jsp/Home.jsp), without being limited thereto.
- the cosmetically active ingredients useful herein can in some instances provide more than one benefit or operate via more than one mode of action.
- cosmetic compositions according to the present invention are in particular skin care preparations, functional preparations and/or hair care preparations such as most in particularly skin or hair care preparations.
- Examples of skin care preparations are, in particular, light protective preparations (sun care preparations), anti-ageing preparations, preparations for the treatment of photoageing, body oils, body lotions, body gels, treatment creams, skin protection ointments, moisturizing preparations such as moisturizing gels or moisturizing sprays, face and/or body moisturizers, make-up as well as skin lightening preparations.
- light protective preparations unsun care preparations
- anti-ageing preparations preparations for the treatment of photoageing
- body oils body lotions, body gels, treatment creams, skin protection ointments
- moisturizing preparations such as moisturizing gels or moisturizing sprays
- face and/or body moisturizers make-up as well as skin lightening preparations.
- Examples of functional preparations are cosmetic compositions containing active ingredients such as hormone preparations, vitamin preparations, vegetable extract preparations, anti-ageing preparations, and/or antimicrobial (antibacterial or antifungal) preparations without being limited thereto.
- hair care preparations which are suitable according to the invention and which may be mentioned are shampoos, hair conditioners (also referred to as hair rinses), hairdressing compositions, hair tonics, hair regenerating compositions, hair lotions, water wave lotions, hair sprays, hair creams, hair gels, hair oils, hair pomades or hair brilliantines. Accordingly, these are always preparations which are applied to the hair and the scalp for a shorter or longer time depending on the actual purpose for which they are used.
- the cosmetic compositions according to the present invention are emulsions and/or gels. Even more preferably, the cosmetic compositions are emulsions which contain an oily phase and an aqueous phase such as in particular O/W, W/O, Si/W, W/Si, O/W/O, W/O/W multiple or a pickering emulsions.
- the amount of the oily phase (i.e. the phase containing all oils and fats including the polar oils) present in such emulsions such as in particular O/W, W/O, Si/W, W/Si, O/W/O, W/O/W multiple or a pickering emulsions is preferably at least 10 wt.-%, such as in the range from 10 to 60 wt.-%, preferably in the range from 15 to 50 wt.-%, most preferably in the range from 15 to 40 wt.-%, based on the total weight of the composition.
- the oil phase according to the invention preferably comprises oils selected from butylenglykoldicaprylatAdicaprat, propylenglykoldicaprylatZ-dicaprat, dicaprylylether, C s-Alkylbenzoat, Ci 8.3 8-fatty acid triglyceride, dibutyladipate, cyclomethicone, dimethicone, 2-phenylethylbenzoat, isopropyl lauroyl sarkosinate, caprylic/ capric triglyceride as well as mixtures thereof.
- the amount of the aqueous phase present in such emulsions is preferably at least 20 wt.-%, such as in the range from 20 to 90 wt.-%, preferably in the range from 30 to 80 wt.-%, most preferably in the range from 30 to 70 wt.-%, based on the total weight of the composition.
- the ratio of oily phase to aqueous phase is selected in the range of 40:60 to 30 to 70.
- the cosmetic compositions according to the present invention are in the form of an oil-in-water (O/W) emulsion comprising an oily phase dispersed in an aqueous phase in the presence of an O/W emulsifier.
- O/W oil-in-water
- the preparation of such O/W emulsions is well known to a person skilled in the art.
- the cosmetic composition according to the invention is an O/W emulsion
- it contains advantageously at least one O/W- or Si/W-emulsifier selected from the list of, glyceryl stearate citrate, glyceryl stearate SE (self-emulsifying), stearic acid, salts of stearic acid, polyglyceryl-3-methylglycosedistearate.
- O/W- or Si/W-emulsifiers selected from the list of, glyceryl stearate citrate, glyceryl stearate SE (self-emulsifying), stearic acid, salts of stearic acid, polyglyceryl-3-methylglycosedistearate.
- phosphate esters and the salts thereof such as cetyl phosphate (e.g. as Amphisol® A from DSM Nutritional Products Ltd.), diethanolamine cetyl phosphate (e.g.
- emulsifiers are sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, cetearyl glucoside, lauryl glucoside, decyl glucoside, sodium stearoyl glutamate, sucrose polystearate and hydrated polyisobutene.
- one or more synthetic polymers may be used as an emulsifier. For example, PVP eicosene copolymer, acrylates/C 10-30 alkyl acrylate crosspolymer, and mixtures thereof.
- the at least one O/W, respectively Si/W emulsifier is preferably used in an amount of 0.5 to 10 wt. %, in particular in the range of 0.5 to 6 wt.-%, such as more in particular in the range of 0.5 to 5 wt.-%, such as most in particular in the range of 1 to 4 wt.-%, based on the total weight of the cosmetic composition.
- Particular suitable O/W emulsifiers to be used in the cosmetic compositions according to the invention encompass phosphate ester emulsifiers such as advantageously 8-10 alkyl ethyl phosphate, C9-15 alkyl phosphate, ceteareth-2 phosphate, ceteareth-5 phosphate, ceteth-8 phosphate, ceteth-10 phosphate, cetyl phosphate, C6-10 pareth- 4 phosphate, C12-15 pareth-2 phosphate, C12-15 pareth-3 phosphate, DEA- ceteareth-2 phosphate, DEA-cetyl phosphate, DEA-oleth-3 phosphate, potassium cetyl phosphate, deceth-4 phosphate, deceth-6 phosphate and trilaureth-4 phosphate.
- phosphate ester emulsifiers such as advantageously 8-10 alkyl ethyl phosphate, C9-15 alkyl phosphate, ceteareth-2 phosphate, ceteare
- a particular suitable O/W emulsifier to be used in the cosmetic compositions according to the invention is potassium cetyl phosphate e.g. commercially available as Amphisol® K at DSM Nutritional Products Ltd Kaiseraugst.
- O/W emulsifiers are non-ionic self-emulsifying systems derived from olive oil e.g. known as (INCI Name) cetearyl olivate and sorbitan olivate (chemical composition: sorbitan ester and cetearyl ester of olive oil fatty acids) sold under the tradename OLIVEM 1000.
- the invention relates to cosmetic compositions with all the definitions and preferences given herein in the form of O/W emulsions comprising an oily phase dispersed in an aqueous phase in the presence of an O/W emulsifier wherein the O/W emulsifier is potassium cetyl phosphate.
- the amount of oily phase in such O/W emulsions is preferably at least 10 wt.-%, more preferably in the range of 10 to 60 wt.-%, most preferably in the range of 15 to 50 wt.-%, such as in the range of 15 to 40 wt.-%, based on the total weight of the composition.
- the cosmetic compositions according to the invention further comprise at least one fatty alcohol (co-emulsifier), such as in particular cetyl alcohol, cetearyl alcohol and/ or behenyl alcohol.
- the total amount of one or several fatty alcohols on the topical compositions according to the invention is preferably selected in the range of about 0.1 to 10.0 wt.-%, in particular in the range of about 0.5 to 6.0 wt.-% with respect to the total weight of the topical composition.
- the topical compositions according to the invention comprise a thickener in particular if the topical composition is in the form of an emulsion to assist in making the consistency of a product suitable.
- Preferred thickeners are aluminiumsilicates, xanthan gum, hydroxypropylmethylcellulose, hydroxyethylcellulose, polyacrylates such as carbopole® (e.g. Carbopole 980, 981 , 1382, 2984, 5984) or mixtures thereof. Further preferred thickeners encompass acrylate/Cio-30 alkyl acrylate copolymers (such as e.g. Pemulen TR 1 , Pemulen TR 2, Carbopol 1328 by. NOVEON) as well as Aristoflex AVC (INCI: Ammonium Acryloyldimethyltaurate/VP Copolymer).
- carbopole® e.g. Carbopole 980, 981 , 1382, 2984, 5984
- Further preferred thickeners encompass acrylate/Cio-30 alkyl acrylate copolymers (such as e.g. Pemulen TR 1 , Pemulen TR 2, Carbopol 1328 by. NOVEON) as
- the cosmetic compositions according to the present invention advantageously comprise a preservative.
- the preservative is preferably used in an amount of 0.1 to 2 wt.-%, more preferably in an amount of 0.5 to 1 .5 wt.-%, based on the total weight of the composition.
- the cosmetic compositions according to the invention in general have a pH in the range of 3 to 10, preferably a pH in the range of 4 to 8 and most preferably a pH in the range of 4 to 7.5 such as in the range of 5 to 6.5.
- the pH can easily be adjusted as desired with suitable acids, such as e.g. citric acid, or bases, such as sodium hydroxide (e.g. as aqueous solution), triethanolamine (TEA Care), Tromethamine (Trizma Base) and Aminomethyl Propanol (AMP-Ultra PC 2000), according to standard methods in the art.
- compositions according to the present invention are free of any parabenes, benzethoniumchlorid, piroctone olamine, lauroylarginat, methylisothiazolinon, chlormethylisothiazolinon, bronopol, benzalkoniumchloride, formaldehyd releasing compounds, salicylic acid, triclosan, DMDM hydantoin, chlorphenesin and IPBC (lodopropinylbutyl carbamate), such as in particular free of methylchloroisothiazolinone.
- the amount of the cosmetic composition to be applied to the skin is not critical and can easily be adjusted by a person skilled in the art.
- the amount is selected in the range of 0.1 to 3 mg/cm 2 skin, such as preferably in the range of 0.1 to 2 mg/cm 2 skin and most preferably in the range of 0.5 to 2 mg/cm 2 skin.
- the following examples are provided to further illustrate the compositions and effects of the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way.
- Table 2 Colour stability upon storage (b-values); 5% HMO
- Table 2 Colour stability upon storage (b-values); 5% HMO
- Table 2 Colour stability upon storage (b-values); 5% HMO
- Table 3 Colour stability upon storage (b-values); 0.5% HMO As can be retrieved from table 3, the HMO’s according to the present invention also led to an improved colour stabilisation at low use levels.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to cosmetic compositions comprising Vitamin B6 or a derivative thereof and at least one human milk oligosaccharide (HMOs) selected from the group consisting of 3'sialyllactose, 6'sialyllactose and lacto-N-tetraose as well as to a use of said HMOs for suppressing discoloration of Vitamin B6 or a derivative thereof.
Description
HUMAN MILK OLIGOSACCAHRIDES IN COSMETICS
The present invention relates to cosmetic compositions comprising Vitamin B6 or a derivative thereof and at least one human milk oligosaccharide (HMOs) selected from the group consisting of 3’sialyllactose, 6’sialyllactose and lacto-N-tetraose as well as to a use of said HMOs for suppressing discoloration of Vitamin B6 or a derivative thereof.
Vitamin B6 or derivatives thereof such as pyridoxine hydrochloride are used in cosmetic applications to exert beneficial physiological effects, such as to stimulate the healthy-looking appearance of hair and contribute to the efficacy of anti-dandruff products. In skin care applications, Vitamin B6 appears to reduce sebum levels and limit the area of oily spots. However, Vitamin B6 tends to discolor upon storage which is highly unwanted as it leads to an unpleasant optical appearance of the respective product.
Human milk oligosaccharides’ (HMOs) are a family of structurally diverse unconjugated glycans that are highly abundant in and unique to human milk. Due to its specific characteristics these HMOs can be used in nutritional, pharmaceutical, cosmetic and medical applications.
In accordance with the present invention it has now surprisingly been found that the discoloration of compositions containing Vitamin B6 respectively derivatives thereof such as in particular pyridoxine hydrochloride can be effectively reduced by the addition of certain human milk oligosaccharides.
Thus, in a first aspect, the present invention relates to cosmetic compositions comprising a human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N-tetraose and Vitamin B6 or a derivative thereof.
In a second aspect the present invention relates to the use of a human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N- tetraose for suppressing discoloration of Vitamin B6 or a derivative thereof, preferably in aqueous compositions and optionally appreciating the effect.
In a third aspect, the present invention relates to a method for reducing discoloration of compositions containing Vitamin B6 and/or a derivative thereof, said method comprising preparing a composition comprising Vitamin B6 and/or a derivative thereof, one or more human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N-tetraose and a cosmetically acceptable carrier, which carrier preferably comprises water, and optionally storing the respective composition for at least 1 , more preferably for at least 2, most preferably for at least 4 weeks, such as e.g. for 6 weeks.
In a further aspect the invention relates to the use of a combination of Vitamin B6 and/or a derivative thereof and one or more human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N-tetraose, for the preparation of storage stable topical composition. These compositions exhibit an excellent storage stability in view of preventing/suppressing discoloration compared to a control not comprising the respective HMO(s). Said compositions can be prepared by admixing Vitamin B6 and/or a derivative thereof and at least one human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N-tetraose into a cosmetically acceptable carrier, which carrier preferably comprises water.
It is well understood, that the compositions according to the present invention may comprise only one HMO as defined herein as well as only one Vitamin B6/ Vitamin B6 derivative, which embodiment is preferred, but also may comprise mixtures of HMOs as well mixtures of Vitamin B6 and its derivatives as defined herein.
The term ‘supress/ suppressing discoloration’ refers to a reduced discoloration of the composition according to the present invention compared to control. The suppression of discoloration according to the present invention is reflected by reduced b-values (according to the CIELAB colorspace) compared to the respective control not comprising the HMO upon storage, such as storage for at least 2 weeks at RT (about 22°C) at daylight in clear glass vials/containers as outlined in the example.
The term Vitamin B6 and derivatives thereof’ refers in particular to pyridoxine hydrochloride [58-56-0], pyridoxal [CAS-Nr. 66-72-8] and pyridoxamin [CAS-Nr. 85-87- 0], In all embodiments, particularly preferred is the use of pyridoxine hydrochloride also known as Vitamin B6 hydrochloride or Vitamin B6 which is e.g. available as Pyridoxine
hydrochloride or Pyridoxine Hydrochloride 98 DC at DSM Nutritional Products AG, (4303 Kaiseraugst, Switzerland).
The term ‘derivative’ as used here is to be understood based on the definition in the Rbmpp's Chemistry Lexicon referring to a chemical compound that can be represented by original compound, e.g. by structurally changing a functional group in usually only a single reaction step (derivatization). A compound and its derivative are accordingly structurally closely related. Said term is clear to a person skilled in the art.
Preferably, the amount of Vitamin B6 or a derivative thereof such as in particular pyridoxine hydrochloride in the compositions according to the present invention is selected in the range of 0.02 to 6 wt. %, preferably in the range of 0.05 to 4wt. %, most preferably in the range of 0.1 to 3 wt. %, based on the total weight of the composition.
HMOs are composed of the five monosaccharides glucose (Glc), galactose (Gal), N- acetylglucosamine (GIcNAc), fucose (Fuc) and sialic acid (Sia), with N-acetylneuraminic acid (Neu5Ac) as the predominant if not only form of Sia. More than two hundred different HMOs have been identified so far.
The term sialyllactoses as used herein refers to sialylated HMO’s as well as salts thereof (preferably the sodium salts) such as in particular 3’sialyllactose, 6’sialyllactose as well as the respective sodium salts thereof (CAS No’s: 35890-39-2 (3’sialyllactose); 128596-80-5 (3’sialyllactose sodium salt); 35890-39-2 (6’sialyllactose); 157574-76-0 (6’sialyllactose sodium salt)). Most preferred in all embodiments of the present invention is the use of 3’sialyllactose sodium salt and/ or 6’sialyllactose sodium salt.
Lacto-N-tetraose (LNT) is a highly abundant neutral core HMO in human milk (CAS No: 141 16-68-8).
HMOs can be isolated from breast milk or they can be produced chemically or biochemically.
For the purpose of the present invention the source of the HMO is not essential. It is clear that HMOs from different sources can be used.
In the embodiment of the present invention the one or more HMO may not only serve as an agent to reduce discoloration but may also excerpt positive effect on the skin.
Preferably in all embodiments of the present invention the HMO is selected from the group consisting of 3’sialyllactose sodium salt and 6'sialyllactose sodium salt as well as mixtures thereof, as these HMOs are particularly effective.
The total amount of HMO(s) according to the present invention in the compositions according to the present invention is preferably selected in the range from 0.01 to 10 wt.-%, more preferably from 0.1 to 7.5 wt.-%, most preferably from 0.2 to 5 wt.-%, based on the total weight of the composition. Further suitable ranges are from 0.25 to 2.5 wt.-%, from 0.5 to 2 wt.-%, from 0.1 to 1 wt.-%, from 0.25 to 0.75 wt.-% and from 0.3 to 0.6 wt.-%. Particularly preferred ranges according to the present invention are from 0.1 to 5 wt.-%, more preferably from 0.25 to 5 wt.-%, such as from 0.3 to 5 wt.-%.
In all embodiments of the present invention, preferably the use level (in weight-%) of the HMO(s) is higher than the one of Vitamin B6 and/or a derivative thereof, i.e. the HMO(s) is/ are used in an excess.
Accordingly, in all embodiments of the present invention, it is preferred that the weightratio (w/w) between the HMO(s) and Vitamin B6 or a derivative thereof is selected in the range from 50:1 to 1 :1 , more preferably in the range from 25:1 to 1 :1 , most preferably in the range from 15:1 to 1 :1 such as from 15:1 to 5: 1. Further preferred ranges are 10:1 to 7.5:1 , 10:1 to 5:1 or 10:1 to 2:1 and 10:1 to 1 :1.
The term ‘cosmetic composition’ as used herein refers to cosmetic compositions which are used to treat, care for or improve the appearance of the skin and/or the scalp.
In all embodiments according to the present invention including all compositions, methods and uses as disclosed herein, the compositions preferably are aqueous compositions, i.e. compositions which comprise water.
Advantageously, in all embodiments of the present invention the water content in the compositions according to the present invention is selected in the range from 30 to 90 wt.-%, from 40 to 90 wt.-%, from 45 to 90 wt.-% or from 50 to 90 wt.-%, based on
the total weight of the composition. Further suitable ranges are from 30 to 75 wt.-%, from 30 to 70 wt.-%, from 30 to 60 wt.-% and from 40 to 60 wt.-%.
In a particular embodiment, the compositions according to the present invention are cosmetic compositions intended to be topically applied to mammalian keratinous tissue such as in particular to human skin or the human scalp. Such compositions are also called dermatological compositions. Thus, preferably in all embodiments of the present invention the cosmetic compositions are topical cosmetic (i.e. dermatological) compositions with all the definitions and preferences as given herein.
The topical compositions according to the present invention may be leave-on or rinse- off compositions, and include any product applied to a human body, primarily for improving appearance, cleansing, odor control or general aesthetics. Preferably the cosmetic compositions of the present invention are leave-on compositions.
It is well understood that the cosmetic compositions according to the invention intended for topical application comprise a physiologically acceptable medium, i.e. a medium compatible with keratinous substances, such as the skin, mucous membranes, and keratinous fibers. In particular, the physiologically acceptable medium is a cosmetically acceptable carrier. In all embodiments of the present invention it is preferred that the carrier comprises water.
The term ‘cosmetically acceptable carrier’ (also referred to herein as carrier) refers to all vehicles/ carriers conventionally used in cosmetic compositions, i.e. which are suitable for topical application to the keratinous tissue, have good aesthetic properties, are compatible with the actives present in the composition, and will not cause any unreasonable safety or toxicity concerns. Such carriers are well-known to one of ordinary skill in the art, and can include one or more compatible liquid(s) or solid filler diluent(s), excipient(s), additive(s) or vehicle(s) which are suitable for application to skin.
The exact amount of carrier will depend upon the actual level of the active ingredients and of any other optional ingredients that one of ordinary skill in the art would classify as distinct from the carrier (e.g., other active ingredients).
The compositions of the present invention preferably comprise from about 50% to about 99.999%, more preferably from about 60% to about 99.99%, still more preferably from 75% to about 99%, and most preferably, from about 80% to about 98% such as about 90% to about 98%, by weight of the composition, of a carrier, based on the total weight of the composition.
In a particular advantageous embodiment, the carrier consists furthermore of at least 30 wt. %, more preferably of at least 40 wt.-%, most preferably of at least 45 wt.-% of water, such as in particular of 50 to 90 wt.-% of water.
The cosmetic compositions in accordance with the invention can be in the form of a liquid, lotion, a thickened lotion, a gel, a cream, a milk, an ointment, a paste, a powder, a make-up, or a solid tube stick and can be optionally be packaged as an aerosol and can be provided in the form of a mousse such as an aerosol mousse, a foam or a spray foam, a spray, a stick.
Preferably Vitamin B6 and/or a derivative thereof and the respective HMO(s) are formulated into lotions, creams, gels, and tonics. These product forms may be used for a number of applications, including, but not limited to, hand and body lotions, facial moisturizers, anti-ageing preparations, make-ups including foundations, and the like. Any additional components required to formulate such products vary with product type and can be routinely chosen by one skilled in the art.
If the cosmetic compositions of the present invention are formulated as an aerosol and applied to the skin as a spray-on product, a propellant is added to the composition.
The cosmetic compositions according to the present invention can be prepared by conventional methods in the art such as e.g. by admixing the Vitamin B6 and/or a derivative thereof and the respective HMO(s) with all the definitions and preferences given herein with the cosmetically acceptable carrier.
The cosmetic composition may comprise further ingredients, which may form part of the carrier. Such ingredients are particularly surfactants, emulsifiers, thickeners, and oils. Such suitable surfactants, emulsifiers, thickeners, and oils are well known to a person skilled in the art.
The cosmetic compositions of the invention (including the carrier) may comprise further conventional (cosmetic) adjuvants and additives, such as preservatives/antioxidants, fatty substances/oils, water, organic solvents, silicones, thickeners, softeners, emulsifiers, antifoaming agents, aesthetic components such as fragrances, surfactants, fillers, anionic, cationic, non-ionic or amphoteric polymers or mixtures thereof, propellants, acidifying or basifying agents, dyes, colorings/colorants, abrasives, absorbents, chelating agents and/ or sequestering agents, essential oils, skin sensates, astringents, pigments or any other ingredients usually formulated into such compositions.
If nothing else is stated, the excipients, additives, diluents, etc. mentioned in the following are suitable for the compositions according to the present invention. The necessary amounts of the cosmetic and dermatological adjuvants and additives can, based on the desired product, easily be determined by the skilled person.
The additional ingredients can either be added to the oily phase, the aqueous phase or separately as deemed appropriate. The mode of addition can easily be adapted by a person skilled in the art.
Examples of cosmetic excipients, diluents, adjuvants, additives as well as active ingredients commonly used in the skin care industry which are suitable for use in the cosmetic compositions of the present invention are for example described in the International Cosmetic Ingredient Dictionary & Handbook by Personal Care Product Council (http://www.personalcarecouncil.org/), accessible by the online INFO BASE (http://online.personalcarecouncil.org/jsp/Home.jsp), without being limited thereto.
The cosmetically active ingredients useful herein can in some instances provide more than one benefit or operate via more than one mode of action.
Of course, one skilled in this art will take care to select the above mentioned optional additional ingredients, adjuvants, diluents and additives and/or their amounts such that the advantageous properties intrinsically associated with the combination in accordance with the invention are not, or not substantially, detrimentally affected by the envisaged addition or additions.
The cosmetic compositions according to the present invention are in particular skin care preparations, functional preparations and/or hair care preparations such as most in particularly skin or hair care preparations.
Examples of skin care preparations are, in particular, light protective preparations (sun care preparations), anti-ageing preparations, preparations for the treatment of photoageing, body oils, body lotions, body gels, treatment creams, skin protection ointments, moisturizing preparations such as moisturizing gels or moisturizing sprays, face and/or body moisturizers, make-up as well as skin lightening preparations.
Examples of functional preparations are cosmetic compositions containing active ingredients such as hormone preparations, vitamin preparations, vegetable extract preparations, anti-ageing preparations, and/or antimicrobial (antibacterial or antifungal) preparations without being limited thereto.
Examples of hair care preparations which are suitable according to the invention and which may be mentioned are shampoos, hair conditioners (also referred to as hair rinses), hairdressing compositions, hair tonics, hair regenerating compositions, hair lotions, water wave lotions, hair sprays, hair creams, hair gels, hair oils, hair pomades or hair brilliantines. Accordingly, these are always preparations which are applied to the hair and the scalp for a shorter or longer time depending on the actual purpose for which they are used.
In a preferred embodiment, the cosmetic compositions according to the present invention are emulsions and/or gels. Even more preferably, the cosmetic compositions are emulsions which contain an oily phase and an aqueous phase such as in particular O/W, W/O, Si/W, W/Si, O/W/O, W/O/W multiple or a pickering emulsions.
The amount of the oily phase (i.e. the phase containing all oils and fats including the polar oils) present in such emulsions such as in particular O/W, W/O, Si/W, W/Si, O/W/O, W/O/W multiple or a pickering emulsions is preferably at least 10 wt.-%, such as in the range from 10 to 60 wt.-%, preferably in the range from 15 to 50 wt.-%, most preferably in the range from 15 to 40 wt.-%, based on the total weight of the composition.
The oil phase according to the invention preferably comprises oils selected from butylenglykoldicaprylatAdicaprat, propylenglykoldicaprylatZ-dicaprat, dicaprylylether, C s-Alkylbenzoat, Ci8.38-fatty acid triglyceride, dibutyladipate, cyclomethicone, dimethicone, 2-phenylethylbenzoat, isopropyl lauroyl sarkosinate, caprylic/ capric triglyceride as well as mixtures thereof.
The amount of the aqueous phase present in such emulsions is preferably at least 20 wt.-%, such as in the range from 20 to 90 wt.-%, preferably in the range from 30 to 80 wt.-%, most preferably in the range from 30 to 70 wt.-%, based on the total weight of the composition.
Advantageously in all emulsions of the present invention the ratio of oily phase to aqueous phase is selected in the range of 40:60 to 30 to 70.
In one particular advantageous embodiment, the cosmetic compositions according to the present invention are in the form of an oil-in-water (O/W) emulsion comprising an oily phase dispersed in an aqueous phase in the presence of an O/W emulsifier. The preparation of such O/W emulsions is well known to a person skilled in the art.
If the cosmetic composition according to the invention is an O/W emulsion, then it contains advantageously at least one O/W- or Si/W-emulsifier selected from the list of, glyceryl stearate citrate, glyceryl stearate SE (self-emulsifying), stearic acid, salts of stearic acid, polyglyceryl-3-methylglycosedistearate. Further suitable emulsifiers are phosphate esters and the salts thereof such as cetyl phosphate (e.g. as Amphisol® A from DSM Nutritional Products Ltd.), diethanolamine cetyl phosphate (e.g. as Amphisol® DEA from DSM Nutritional Products Ltd.), potassium cetyl phosphate (e.g. as Amphisol® K from DSM Nutritional Products Ltd.), sodium cetearylsulfate, sodium glyceryl oleate phosphate, hydrogenated vegetable glycerides phosphate and mixtures thereof. Further suitable emulsifiers are sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, cetearyl glucoside, lauryl glucoside, decyl glucoside, sodium stearoyl glutamate, sucrose polystearate and hydrated polyisobutene. Furthermore, one or more synthetic polymers may be used as an emulsifier. For example, PVP eicosene copolymer, acrylates/C 10-30 alkyl acrylate crosspolymer, and mixtures thereof.
The at least one O/W, respectively Si/W emulsifier is preferably used in an amount of
0.5 to 10 wt. %, in particular in the range of 0.5 to 6 wt.-%, such as more in particular in the range of 0.5 to 5 wt.-%, such as most in particular in the range of 1 to 4 wt.-%, based on the total weight of the cosmetic composition.
Particular suitable O/W emulsifiers to be used in the cosmetic compositions according to the invention encompass phosphate ester emulsifiers such as advantageously 8-10 alkyl ethyl phosphate, C9-15 alkyl phosphate, ceteareth-2 phosphate, ceteareth-5 phosphate, ceteth-8 phosphate, ceteth-10 phosphate, cetyl phosphate, C6-10 pareth- 4 phosphate, C12-15 pareth-2 phosphate, C12-15 pareth-3 phosphate, DEA- ceteareth-2 phosphate, DEA-cetyl phosphate, DEA-oleth-3 phosphate, potassium cetyl phosphate, deceth-4 phosphate, deceth-6 phosphate and trilaureth-4 phosphate.
A particular suitable O/W emulsifier to be used in the cosmetic compositions according to the invention is potassium cetyl phosphate e.g. commercially available as Amphisol® K at DSM Nutritional Products Ltd Kaiseraugst.
Another particular suitable class of O/W emulsifiers are non-ionic self-emulsifying systems derived from olive oil e.g. known as (INCI Name) cetearyl olivate and sorbitan olivate (chemical composition: sorbitan ester and cetearyl ester of olive oil fatty acids) sold under the tradename OLIVEM 1000.
In one particular embodiment, the invention relates to cosmetic compositions with all the definitions and preferences given herein in the form of O/W emulsions comprising an oily phase dispersed in an aqueous phase in the presence of an O/W emulsifier wherein the O/W emulsifier is potassium cetyl phosphate. The amount of oily phase in such O/W emulsions is preferably at least 10 wt.-%, more preferably in the range of 10 to 60 wt.-%, most preferably in the range of 15 to 50 wt.-%, such as in the range of 15 to 40 wt.-%, based on the total weight of the composition.
Preferably, the cosmetic compositions according to the invention further comprise at least one fatty alcohol (co-emulsifier), such as in particular cetyl alcohol, cetearyl alcohol and/ or behenyl alcohol. The total amount of one or several fatty alcohols on the topical compositions according to the invention is preferably selected in the range of about 0.1 to 10.0 wt.-%, in particular in the range of about 0.5 to 6.0 wt.-% with respect to the total weight of the topical composition.
Preferably, the topical compositions according to the invention comprise a thickener in particular if the topical composition is in the form of an emulsion to assist in making the consistency of a product suitable. Preferred thickeners are aluminiumsilicates, xanthan gum, hydroxypropylmethylcellulose, hydroxyethylcellulose, polyacrylates such as carbopole® (e.g. Carbopole 980, 981 , 1382, 2984, 5984) or mixtures thereof. Further preferred thickeners encompass acrylate/Cio-30 alkyl acrylate copolymers (such as e.g. Pemulen TR 1 , Pemulen TR 2, Carbopol 1328 by. NOVEON) as well as Aristoflex AVC (INCI: Ammonium Acryloyldimethyltaurate/VP Copolymer).
The cosmetic compositions according to the present invention advantageously comprise a preservative. When present, the preservative is preferably used in an amount of 0.1 to 2 wt.-%, more preferably in an amount of 0.5 to 1 .5 wt.-%, based on the total weight of the composition.
The cosmetic compositions according to the invention in general have a pH in the range of 3 to 10, preferably a pH in the range of 4 to 8 and most preferably a pH in the range of 4 to 7.5 such as in the range of 5 to 6.5. The pH can easily be adjusted as desired with suitable acids, such as e.g. citric acid, or bases, such as sodium hydroxide (e.g. as aqueous solution), triethanolamine (TEA Care), Tromethamine (Trizma Base) and Aminomethyl Propanol (AMP-Ultra PC 2000), according to standard methods in the art.
In a particular advantageous aspect, the compositions according to the present invention are free of any parabenes, benzethoniumchlorid, piroctone olamine, lauroylarginat, methylisothiazolinon, chlormethylisothiazolinon, bronopol, benzalkoniumchloride, formaldehyd releasing compounds, salicylic acid, triclosan, DMDM hydantoin, chlorphenesin and IPBC (lodopropinylbutyl carbamate), such as in particular free of methylchloroisothiazolinone.
The amount of the cosmetic composition to be applied to the skin is not critical and can easily be adjusted by a person skilled in the art. Preferably the amount is selected in the range of 0.1 to 3 mg/cm2 skin, such as preferably in the range of 0.1 to 2 mg/cm2 skin and most preferably in the range of 0.5 to 2 mg/cm2 skin.
The following examples are provided to further illustrate the compositions and effects of the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way.
Examples
The formulations as outlined in table 1 were prepared and then stored in clear glass vials at RT (about 22°C) at daylight. The colour stability was assessed by measuring the b values (L* a* b* values/ CIELAB system) after two weeks and after 6 weeks storage (which is an indicator of the discoloration of the sample: the higher the b-value, the higher the discoloration), compared to a control not containing a HMO.
Abbreviations of HMO’s
3’SL: 3'-Sialyllactose sodium salt
6’SL: 6'-Sialyllactose sodium salt
LNnT : Lacto-N-neotetraose
LNT : Lacto-N-tetraose
Mix A and stir until a clear solution is obtained
Add B if necessary at RT to A and stir until a clear solution is obtained
Adjust the pH with C to about 5.5
Table 2: Colour stability upon storage (b-values); 5% HMO
As can be retrieved from table 2, only the HMO’s according to the present invention led to a reduction in the discoloration compared to control, even after 6 weeks of storage. The same experiment has been repeated using 0.5% of the respective HMO. The results are illustrated in table 3 below:
Claims
Claims . A cosmetic composition for topical application comprising Vitamin B6 and/or a derivative thereof and one or more human milk oligosaccharides selected from the group consisting of sialyllactoses and lacto-N-tetraose. . The cosmetic composition according to claim 1 , wherein the Vitamin B6 or derivative thereof is pyridoxine hydrochloride. . The cosmetic composition according to claim 1 or 2, wherein at least one human milk oligosaccharide is 3’sialyllactose sodium salt or 6’sialyllactose sodium salt. . The cosmetic composition according to any one of the preceding claims, wherein the total amount of Vitamin B6 and/or a derivative thereof is selected in the range from 0.02 to 6 wt. %, preferably from 0.05 to 4 wt. %, most preferably from 0.1 to 3 wt. %, based on the total weight of the composition. . The cosmetic composition according to any one of the preceding claims, wherein the total amount of human milk oligosaccharide(s) is selected in the range from 0.01 to 10 wt.-%, preferably from 0.1 to 7.5 wt.-%, most preferably from 0.2 to 5 wt.-%, based on the total weight of the composition. . The cosmetic composition according to any one of the preceding claims, wherein the weight-ratio between the human milk oligosaccharides and Vitamin B6 and/or a derivative thereof is selected in the range from 50:1 to 1 :1 , preferably from 25:1 to 1 :1 , most preferably from 15:1 to 1 :1. . The cosmetic composition according to any one of the preceding claims, wherein the composition comprises a carrier consisting of at least 30 wt. %, more preferably of at least 40 wt.-%, most preferably of at least 45 wt.-% of water, such as in particular of 50 to 90 wt.-% of water. . The cosmetic composition according to any one of the preceding claims, wherein the composition is an O/W emulsion comprising an oily phase dispersed in an aqueous phase.
9. Use of a human milk oligosaccharide selected from the group consisting of sialyllactoses and lacto-N-tetraose for suppressing discoloration of Vitamin B6 and/or a derivative thereof, preferably in aqueous compositions.
10. A method for reducing discoloration of compositions containing Vitamin B6 and/or a derivative thereof, comprising preparing a composition comprising Vitamin B6 and/or a derivative thereof, a human milk oligosaccharide selected from the group consisting of sialyllactose and lacto-N-tetraose, preferably 3’sialyllactose sodium salt and 6’sialyllactose sodium salt and a cosmetically acceptable carrier.
1 1 . The method according to claim 10 wherein the Vitamin B6 or derivative thereof is pyridoxine hydrochloride.
12. The method according to claim 10 or 1 1 , wherein the amount of the Vitamin B6 and/or a derivative thereof is selected in the range from 0.02 to 6 wt. %, preferably from 0.05 to 4 wt. %, most preferably from 0.1 to 3 wt. %, based on the total weight of the composition.
13. The method according to any one of claims 10 to 12, wherein the total amount of human milk oligosaccharide(s) is selected in the range from 0.01 to 10 wt.-%, preferably from 0.1 to 7.5 wt.-%, most preferably from 0.2 to 5 wt.-%, based on the total weight of the composition.
14. The method according to any one of claims 10 to 13, wherein the weight-ratio between the human milk oligosaccharide(s) and Vitamin B6 and/or a derivative thereof is selected in the range from 50:1 to 1 :1 , preferably from 25: 1 to 1 :1 , most preferably from 15:1 to 1 :1.
15. The method according to anyone of claims 10 to 14, wherein the carrier consists of at least 30 wt. %, more preferably of at least 40 wt.-%, most preferably of at least 45 wt.-% of water, such as in particular of 50 to 90 wt.-% of water.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21192703.3 | 2021-08-24 | ||
EP21192703 | 2021-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023025799A1 true WO2023025799A1 (en) | 2023-03-02 |
Family
ID=77465836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/073480 WO2023025799A1 (en) | 2021-08-24 | 2022-08-23 | Human milk oligosaccahrides in cosmetics |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023025799A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1086693A1 (en) * | 1999-09-21 | 2001-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof |
JP2016027007A (en) * | 2014-07-01 | 2016-02-18 | エーザイフード・ケミカル株式会社 | Vitamin B12-containing composition |
US20190247409A1 (en) * | 2016-07-28 | 2019-08-15 | Fonterra Co-Operative Group Limited | Dairy product and process |
-
2022
- 2022-08-23 WO PCT/EP2022/073480 patent/WO2023025799A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1086693A1 (en) * | 1999-09-21 | 2001-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof |
JP2016027007A (en) * | 2014-07-01 | 2016-02-18 | エーザイフード・ケミカル株式会社 | Vitamin B12-containing composition |
US20190247409A1 (en) * | 2016-07-28 | 2019-08-15 | Fonterra Co-Operative Group Limited | Dairy product and process |
Non-Patent Citations (2)
Title |
---|
DATABASE GNPD [online] MINTEL; 1 July 2021 (2021-07-01), ANONYMOUS: "Follow-On Formula for Infants with Special Nutritional Needs", XP055887703, retrieved from https://www.gnpd.com/sinatra/recordpage/8830267/ Database accession no. 8830267 * |
DATABASE GNPD [online] MINTEL; 16 October 2019 (2019-10-16), ANONYMOUS: "Soothing Relief Gel", XP055885709, retrieved from https://www.gnpd.com/sinatra/recordpage/6902013/ Database accession no. 6902013 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5919438A (en) | Dermatological/cosmetic compositions comprising antifungal and antibacterial compounds and reduction of hair loss therewith | |
JP7286907B2 (en) | topical composition | |
WO2023144301A1 (en) | Novel use | |
EP0904054B1 (en) | USE OF alpha-ALKYLGLUCOSIDES AND alpha-ALKYLGLUCOSIDE ESTERS AS ANTI-MICROBIAL EMULSIFYING AGENTS | |
DE19634019A1 (en) | Antimicrobial, antiviral, antiparasitic and antiprotozoal agents | |
US20210000731A1 (en) | Topical composition | |
US9578878B2 (en) | Antimicrobial efficacy of an oregano oil and caprylic acid blend | |
WO2023025799A1 (en) | Human milk oligosaccahrides in cosmetics | |
EP3383355B1 (en) | Use of additives for effective preservation/boost effect of existing preservation of cosmetic emulsions | |
AU2018382466A1 (en) | Propanediol monoacetate mononitrate | |
WO2023025797A1 (en) | Human milk oligosaccharides and vitamin b12 composition | |
WO2023025802A1 (en) | Use of human milk oligosaccharides for suppressing discoloration | |
WO2023025796A1 (en) | Ascorbic acid and human milk oligosaccahride compositions | |
US10933002B2 (en) | Preservation booster | |
EP4392008A1 (en) | Sialyllactose and vitamin c comprising cosmetic composition | |
US20230149274A1 (en) | An antimicrobial composition for tackling malodour | |
WO2023198854A1 (en) | Novel use of psicose | |
WO2023198855A1 (en) | Novel use of a blend of psicose,mannose, fructose and glucose | |
JP2022532308A (en) | Topical composition | |
WO2019007792A1 (en) | Topical compositions | |
WO2023165983A1 (en) | Novel use of 4-amidino benzylamines | |
WO2023099793A1 (en) | Novel compositions comprising retinoids | |
JP2022156953A (en) | external composition | |
WO2020229262A1 (en) | Topical compositions | |
KR20240141194A (en) | New Uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22769582 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22769582 Country of ref document: EP Kind code of ref document: A1 |